Pfizer Quality Improvement Request for Proposals: Improving the Quality and Standardization of Pneumococcal Diagnostic Pathways in Pediatric and Adult Populations
Pfizer Inc.'s grant supports projects in Italy to standardize and improve pneumococcal diagnostic pathways, data quality, and clinician-laboratory collaboration for pediatric and adult care.
Funder: Pfizer Inc.
Due Dates: October 19, 2026 (Full application due by 23:59 EST)
Funding Amounts: Up to EUR 50,000 per project; total RFP budget EUR 300,000; max project duration 2 years.
Summary: Supports quality improvement projects to standardize and optimize pneumococcal diagnostic pathways, data integration, and clinician-laboratory collaboration in Italy.
Key Information: Only institutions in Italy are eligible; clinical research/efficacy studies are excluded.
Description
This funding opportunity from Pfizer Inc. seeks proposals to improve the quality and standardization of microbiological diagnostic pathways for pneumococcal disease in both pediatric and adult populations in Italy. The focus is on implementing evidence-based practices, optimizing diagnostic processes, improving data quality, and fostering collaboration between clinicians and laboratories. Projects should address gaps in diagnostic performance by adopting standardized diagnostic bundles, integrating advanced diagnostic tools, and developing educational and training resources. Emphasis is placed on improving sample management, enhancing data integration, and disseminating standard operating procedures to support high-quality serotype surveillance and strengthen both institutional and public health reporting.
